TriSalus Life Sciences Future Growth
Future criteria checks 5/6
TriSalus Life Sciences is forecast to grow earnings and revenue by 70.1% and 27.8% per annum respectively while EPS is expected to grow by 72.8% per annum.
Key information
70.1%
Earnings growth rate
72.77%
EPS growth rate
| Biotechs earnings growth | 25.2% |
| Revenue growth rate | 27.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 13 Jul 2026 |
Recent future growth updates
Recent updates
TLSI: Future Clinical Data And Product Approvals Will Drive Rebound
Analysts have trimmed their fair value estimate for TriSalus Life Sciences, reflecting a reduction in the Street price target to $8 from $10. They reset revenue and AEBITDA expectations while still pointing to potential support from future clinical data and product approvals.
TLSI: PREDICTT Trial Progress Will Drive Future Rebound Potential
Analysts have lowered their fair value estimate for TriSalus Life Sciences from $11.50 to $8.80 and price targets from $10 to $8, citing updated revenue and AEBITDA expectations. They still see potential support from 30% growth in the second half, new clinical data, and possible product approvals.Long Term Embolization Trends And New Indications Will Reshape This Undervalued Medtech Story
Catalysts About TriSalus Life Sciences TriSalus Life Sciences develops and commercializes pressure enabled drug delivery technologies and catheters used in interventional procedures for solid tumors and other vascular conditions. What are the underlying business or industry changes driving this perspective?TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks
Summary TriSalus Life Sciences aims to achieve positive cash flow by 2025, driven by expanding sales of their TriNav system and reducing operating expenses. The PERIO-03 trial for nelitolimod, a potential treatment for liver-involved cancers, is a key catalyst, with top-line data expected later this year. Financially, TLSI reported a net loss of $30 million for FY 2024, but expects to be EBITDA positive with 50% sales growth in 2025. Despite risks like low cash reserves and potential dilution, I maintain a "buy" rating, contingent on continued sales growth and stable financial reporting. Read the full article on Seeking AlphaTriSalus Life Sciences: Falling Despite Moving Forward Into The Market
Summary TriSalus Life Sciences, Inc. is focusing on developing organ-targeted therapy delivery mechanisms and pairing them with their own drugs. Nelitolimod, a TLR9 activator, is showing promising results in various solid tumor contexts, including liver and pancreatic cancers. Despite financial concerns, TriSalus Life Sciences' growing sales and promising clinical data make them a potential bargain investment when considered for the longer term. Read the full article on Seeking AlphaEarnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 109 | 15 | 17 | 28 | 3 |
| 12/31/2027 | 79 | -9 | 3 | 13 | 4 |
| 12/31/2026 | 52 | -17 | 1 | -14 | 4 |
| 3/31/2026 | 45 | -57 | -20 | -20 | N/A |
| 12/31/2025 | 45 | -70 | -19 | -18 | N/A |
| 9/30/2025 | 40 | -71 | -22 | -21 | N/A |
| 6/30/2025 | 36 | -33 | -29 | -28 | N/A |
| 3/31/2025 | 32 | -30 | -36 | -34 | N/A |
| 12/31/2024 | 29 | -33 | -41 | -41 | N/A |
| 9/30/2024 | 27 | -59 | -45 | -44 | N/A |
| 6/30/2024 | 25 | -58 | -56 | -55 | N/A |
| 3/31/2024 | 22 | -68 | -52 | -51 | N/A |
| 12/31/2023 | 19 | -64 | -51 | -51 | N/A |
| 9/30/2023 | 16 | -53 | -50 | -50 | N/A |
| 6/30/2023 | 15 | -59 | -34 | -33 | N/A |
| 3/31/2023 | 13 | -51 | -33 | -32 | N/A |
| 12/31/2022 | 12 | -50 | -33 | -32 | N/A |
| 9/30/2022 | 12 | -32 | -30 | -28 | N/A |
| 12/31/2021 | 8 | -29 | -24 | -23 | N/A |
| 12/31/2020 | 5 | -32 | -16 | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TLSI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).
Earnings vs Market: TLSI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TLSI is expected to become profitable in the next 3 years.
Revenue vs Market: TLSI's revenue (27.8% per year) is forecast to grow faster than the US market (12.7% per year).
High Growth Revenue: TLSI's revenue (27.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TLSI's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/15 06:48 |
| End of Day Share Price | 2026/07/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TriSalus Life Sciences, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Justin Walsh | JonesTrading Institutional Services, LLC |
| Frank Takkinen | Lake Street Capital Markets, LLC |